1.79
-2.19%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aytu Biopharma
From its filings with the US Securities and Exchange Commission
Aytu Biopharma is based in Denver, Colorado and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AYTU. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2026, it reported revenue of $57.6m and a net loss of $14.3m. At that date it held total assets of $105.0m and shareholders' equity of $35.3m.
Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market LLC (the “Nasdaq”) under the ticker symbol “AYTU.” Our principal office is located at 7900 East Union Avenue, Suite 920, Denver, Colorado 80237, and our telephone number is (720) 437-6580.
Our strategy is to become a leading pharmaceutical company that improves the lives of patients. We use a focused approach of in-licensing, acquiring, developing and commercializing novel prescription therapeutics in order to continue building our portfolio of revenue-generating products and leveraging our commercial team’s expertise to launch and build leading brands within large therapeutic markets. In June 2025, we entered into an Exclusive Commercialization Agreement (the “Commercialization Agreement”) with Fabre-Kramer Holdings, Inc. (“Fabre-Kramer”) to commercialize EXXUA ("Gepirone") extended-release tablets (“EXXUA”) in the United States.
Quoted from its 10-K, filed 22 Sept 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Oct 2017
- Employees
- 82
- Website
- aytubio.com ↗
- Head office
- 7900 E. UNION AVENUE, DENVER, CO, 80237
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. John DonofrioIndependent Chairman of the Board$107,595
- Mr. Joshua DisbrowChief Executive Officer, Director, since 2015$928,217
- Mr. Ryan SelhornChief Financial Officer, Treasurer, Corporate Secretary
- Mr. Jarrett DisbrowChief Business Officer, since 2015$542,097
- Mr. Greg PyszczymukaChief Commercial Officer$516,301
- Mr. Carl DockeryIndependent Director$72,595
- Mr. Abhinav JianIndependent Director$79,297
- Ms. Vivian LiuIndependent Director$77,595
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 20
- Environment
- 21
- Social
- 18
- Governance
- 19
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aytu BioScience focuses on ADHD and pediatric markets with Adzenys XR-ODT and Cotempla XR-ODT products.
- The company markets Karbinal ER for allergic conditions and Poly-Vi-Flor for fluoride deficiency in children.
- Aytu employs 82 full-time employees in Englewood, Colorado, supporting specialty pharmaceutical operations.
Weaknesses
- Aytu BioScience's portfolio is limited to ADHD and pediatric products without broader therapeutic areas.
- The company's focus on a narrow market segment may restrict growth opportunities.
- Aytu's employee count of 82 is relatively small for a pharmaceutical firm.
Opportunities
- Expanding into new therapeutic areas beyond ADHD and pediatric markets could increase market share.
- Aytu could leverage its existing pediatric product lines to enter international markets.
- The growing demand for ADHD treatments presents a significant opportunity for Aytu.
Threats
- Competition from larger pharmaceutical companies in the ADHD market poses a risk to Aytu's market position.
- Regulatory changes in the pharmaceutical industry could impact product approvals and sales.
- Aytu's reliance on a limited product portfolio increases vulnerability to market shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.